Anvisa releases rimegepant to treat and prevent migraines as an oral tablet

Agência Nacional of Vigilância Sanitária (Anvisa) approved the registration of Nurtec ODT, a medicine indicated for the treatment and prevention of migraine attacks. The publication came out on Diário Oficial from União on Monday (25). The drug is produced by Pfizer and contains rimegepant hemisulfate sesquihydrate, a molecule belonging to the class of CGRP antagonists.
The medication works by blocking the action of the CGRP protein, involved in the transmission of pain and inflammation during migraine attacks. Diferentemente of blockers already available in Brasil, mostly injectable, Nurtec is an orodispersible tablet that dissolves in the mouth and offers dual functionality: acute treatment and prevention in a single oral medication.
Diferenciais of the new drug
The main difference of Nurtec lies in the combination of acute treatment with prevention, as explained by neurologist Sara Casagrande, member of Sociedade Brasileira, Cefaleias and International Headache Society. Diferente of the CGRP blockers already available in the country, which are mostly injectable, this tablet offers practicality and flexibility of use.
The medication does not cause vasoconstriction
narrowing of blood vessels that restricts the use of traditional medicines in patients at cardiovascular risk. Isso expands safety in vulnerable populations. The drug is specific for migraines and acts directly on the inflammatory mechanism, differentiating itself from common analgesics.
Anvisa approved presentations include:
- Cartelas with 2 tablets
- Cartelas with 8 tablets
- Cartelas with 16 tablets
- Dosagem: 75 mg
The registration is valid until May 2036.
Eficácia proven in clinical studies
A phase 3 study published in the journal The Lancet evaluated the effectiveness of the orodispersible tablet in adults with a history of migraines. Participants received a single dose of 75 mg or placebo during attacks of moderate or severe intensity. Após 2 hours, 21% of those treated with rimegepant were pain free, versus 11% in the placebo group.
Improvement in symptoms considered most bothersome by patients was also documented. Náusea, sensitivity to light or sound improved in 35% of cases treated with the drug, compared to 27% in the placebo group. The most frequent adverse events were nausea and urinary infection, both with a low incidence, and no serious events related to the medication were recorded by the researchers.
Gepants: new class of migraine drugs
Rimegepant is part of the class of “gepants”, drugs developed specifically for migraines. Outros drugs from the same class await regulatory approval in Brasil. Expectations among experts had been high for years, as Brazilian patients imported the medicine on their own before national approval.
Ainda there is no confirmed information about the price or the start date of commercialization in the Brazilian market.






